Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies (Nasdaq: TSHA), a clinical-stage biotech company developing AAV-based gene therapies for CNS diseases, has granted a stock option to a new employee. The inducement grant includes options to purchase 90,000 shares at an exercise price of $2.63 per share under the company's 2023 Inducement Plan.
The stock option has a 10-year term with a four-year vesting schedule: 25% vesting after one year and the remaining 75% vesting monthly over the following 36 months, subject to continued employment.
Taysha Gene Therapies (Nasdaq: TSHA), un'azienda biotecnologica in fase clinica che sviluppa terapie geniche basate su AAV per malattie del sistema nervoso centrale, ha concesso un'opzione su azioni a un nuovo dipendente. La concessione incentivante prevede opzioni per l'acquisto di 90.000 azioni a un prezzo di esercizio di 2,63 $ per azione, nell'ambito del Piano Incentivante 2023 della societ脿.
L'opzione su azioni ha una durata di 10 anni con un piano di maturazione quadriennale: il 25% matura dopo un anno e il restante 75% matura mensilmente nei successivi 36 mesi, subordinato alla continuazione del rapporto di lavoro.
Taysha Gene Therapies (Nasdaq: TSHA), una empresa biotecnol贸gica en fase cl铆nica que desarrolla terapias g茅nicas basadas en AAV para enfermedades del sistema nervioso central, ha otorgado una opci贸n sobre acciones a un nuevo empleado. La concesi贸n por incentivo incluye opciones para comprar 90,000 acciones a un precio de ejercicio de $2.63 por acci贸n bajo el Plan de Incentivos 2023 de la compa帽铆a.
La opci贸n sobre acciones tiene un plazo de 10 a帽os con un calendario de adquisici贸n de derechos de cuatro a帽os: el 25% se adquiere despu茅s de un a帽o y el 75% restante se adquiere mensualmente durante los siguientes 36 meses, sujeto a la continuidad del empleo.
Taysha Gene Therapies (雮橃姢雼�: TSHA)電� 欷戩稊鞁犼步瓿� 歆堩櫂鞚� 鞙勴暅 AAV 旮半皹 鞙犾爠鞛� 旃橂鞝滊ゼ 臧滊皽頃橂姅 鞛勳儊 雼硠鞚� 氚旍澊鞓ろ厡韥� 旮办梾鞙茧, 鞁犾瀰 歆侅洂鞐愱矊 欤检嫕 毵れ垬靹犿儩甓岇潉 攵�鞐枅鞀惦媹雼�. 鞚胳劶韹半笇 攵�鞐棎電� 須岇偓鞚� 2023雲� 鞚胳劶韹半笇 頂岆灉鞐� 霐半澕 90,000欤�毳� 欤茧嫻 $2.63鞚� 頄夓偓臧�瓴╈溂搿� 毵れ垬頃� 靾� 鞛堧姅 鞓奠厴鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
鞚� 欤检嫕 毵れ垬靹犿儩甓岇潃 10雲� 毵岅赴鞚措┌ 4雲� 甓岆Μ頇曥爼 鞚检爼鞚� 鞝侅毄霅╇媹雼�: 1雲� 頉� 25%臧� 甓岆Μ頇曥爼霅橁碃, 雮橂ǜ歆� 75%電� 鞚错泟 36臧滌洈 霃欖晥 毵れ洈 甓岆Μ頇曥爼霅橂┌, 瓿勳啀 瓿犾毄 靸來儨鞐暭 頃╇媹雼�.
Taysha Gene Therapies (Nasdaq : TSHA), une soci茅t茅 biotechnologique en phase clinique d茅veloppant des th茅rapies g茅niques 脿 base d'AAV pour les maladies du syst猫me nerveux central, a accord茅 une option d'achat d'actions 脿 un nouvel employ茅. La subvention d'incitation comprend des options d'achat de 90 000 actions 脿 un prix d'exercice de 2,63 $ par action dans le cadre du Plan d'incitation 2023 de la soci茅t茅.
L'option d'achat d'actions a une dur茅e de 10 ans avec un calendrier d'acquisition sur quatre ans : 25 % acquis apr猫s un an et les 75 % restants acquis mensuellement sur les 36 mois suivants, sous r茅serve de la poursuite de l'emploi.
Taysha Gene Therapies (Nasdaq: TSHA), ein biotechnologisches Unternehmen in der klinischen Entwicklungsphase, das AAV-basierte Gentherapien f眉r Erkrankungen des zentralen Nervensystems entwickelt, hat einem neuen Mitarbeiter eine Aktienoption gew盲hrt. Die Anreizzuteilung umfasst Optionen zum Kauf von 90.000 Aktien zu einem Aus眉bungspreis von 2,63 $ pro Aktie im Rahmen des Inducement-Plans 2023 des Unternehmens.
Die Aktienoption hat eine Laufzeit von 10 Jahren mit einem vierj盲hrigen Vesting-Zeitplan: 25% wird nach einem Jahr f盲llig, die restlichen 75% werden 眉ber die folgenden 36 Monate monatlich vestiert, vorbehaltlich einer fortgesetzten Anstellung.
- None.
- None.
DALLAS, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on August 1, 2025, the Compensation Committee of Taysha's Board of Directors granted one new employee an option to purchase 90,000 shares of the Company's common stock in connection with their employment. The stock option was granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individual entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option has an exercise price of
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company鈥檚 management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit鈥�
Company Contact:
Hayleigh Collins
Senior Director, Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
Media Contact:
Carolyn Hawley
Inizio Evoke
FAQ
What stock options did Taysha Gene Therapies (TSHA) grant to its new employee?
What is the vesting schedule for TSHA's new employee stock options?
What is Taysha Gene Therapies' (TSHA) main business focus?
Under which plan were the TSHA stock options granted?
